00:00Epilepsy treatment lives in a traditional empirical phase with anti-crisis drugs, which are symptomatic drugs for both acute and symptomatic epileptic crises.
00:16That is, the patient who, perhaps for a stroke, comes to the emergency room for those who have sub-entering epileptic crises.
00:24And so we have the drugs that, fortunately, manage to stop the cluster of crises.
00:31And in addition we have the drugs that act instead on epilepsy syndromes and therefore on the genesis of epilepsy.
00:39Here, in this sense, research is moving forward.
00:41To date, we have only one drug that modifies the disease.
00:45In the case of tuberous sclerosis, it is an epileptogenic encephalopathy.
00:50But research is moving forward.
00:53Even if we have drugs that are specific for some epileptic syndromes,
00:58I can think of Travert's syndrome or Lennox-Gastaut's syndrome,
01:02always in epileptogenic encephalopathies,
01:07even if they do not modify the course of the disease.
01:10But probably in the next 2-3 years, research is taking giant steps.
01:16And we could also have on the market drugs that, perhaps, modify the course of the disease
01:22without treating the symptom exclusively.
Comments